Research Summary

I am an academic neuro-oncologist, focused on caring for adult patients with primary brain tumors. In addition to my neurology and neuro-oncology training, I also have a Masters in Public Health (MPH), which I apply to clinical trial development and analysis. I am very active in research areas of novel treatment strategies to improve outcomes for patients with gliomas. I collaborate and serve as the principle investigator on several investigator-initiated, industry-sponsored, and consortia trials. I am involved in the UCSF federal SPORE grant investigating novel ways of investigating the relationship of the immune system with glioma. I also lead our research efforts investigating strategies for improving cognition, quality-of-life, and palliative care for our patients, as well as their caregivers. 


  • Randolph-Macon Woman's College, B.S., 06/2001, Biology 
  • University of Kentucky College of Medicine, 06/2007, M.D. 
  • University of Virginia, Residency, 06/2011, Neurology 
  • Massachusetts General Hospital/Dana Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Fellowship, 06/2014, Neuro-Oncology 
  • Harvard School of Public Health, 06/2014, MPH 

Honors & Awards

  • 2007
    General Clinical Research Center Medical/Dental Mentorship Award, University of Kentucky College of Medicine
  • 2010
    Chief resident in Neurology, University of Virginia College of Medicine
  • 2012
    K12 training grant recipient, "Training Program in Nervous System Tumors", Massachusetts General Hospital

Selected Publications

  1. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 Jul 03.  View on PubMed
  2. Crooms RC, Taylor JW, Jette N, Morgenstern R, Agarwal P, Goldstein NE, Vickrey BG. Palliative care referral across the disease trajectory in high-grade glioma. J Neurooncol. 2023 May; 163(1):249-259.  View on PubMed
  3. Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D. Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study. Future Oncol. 2023 Jan; 19(2):173-188.  View on PubMed
  4. Taylor JW. Neuro-oncology is a team sport: Is it time we added lifestyle coaches? Neurooncol Pract. 2023 Jun; 10(3):217-218.  View on PubMed
  5. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 03; 29(3):615-622.  View on PubMed
  6. Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, Lafontaine M, Luks T, Ammanuel S, Kakaizada S, Egladyous A, Gogos A, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Crane J, Wrensch M, Wiencke JK, Daras M, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Jakola AS, Kavouridis VK, Nawabi N, Solheim O, Smith T, Berger MS, Molinaro AM. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol. 2023 04 10; 41(11):2029-2042.  View on PubMed
  7. Avalos LN, Luks TL, Gleason T, Damasceno P, Li Y, Lupo JM, Phillips J, Oberheim Bush NA, Taylor JW, Chang SM, Villanueva-Meyer JE. Longitudinal MR spectroscopy to detect progression in patients with lower-grade glioma in the surveillance phase. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac175.  View on PubMed
  8. Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022 11 02; 24(11):1935-1949.  View on PubMed
  9. Tang E, Wiencke JK, Warrier G, Hansen H, McCoy L, Rice T, Bracci PM, Wrensch M, Taylor JW, Clarke JL, Koestler DC, Salas LA, Christensen BC, Kelsey KT, Molinaro AM. Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker. Clin Epigenetics. 2022 10 28; 14(1):136.  View on PubMed
  10. Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG, Galanis E. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol. 2023 01 20; 41(3):618-628.  View on PubMed
  11. Taylor JW, Weyer-Jamora C, Hervey-Jumper S. Molecularly determining cognition in glioma: New insights as the plot thickens. Neuro Oncol. 2022 10 03; 24(10):1671-1672.  View on PubMed
  12. Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022 10 03; 24(10):1749-1762.  View on PubMed
  13. Wiencke JK, Molinaro AM, Warrier G, Rice T, Clarke J, Taylor JW, Wrensch M, Hansen H, McCoy L, Tang E, Tamaki SJ, Tamaki CM, Nissen E, Bracci P, Salas LA, Koestler DC, Christensen BC, Zhang Z, Kelsey KT. DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival. Nat Commun. 2022 09 20; 13(1):5505.  View on PubMed
  14. Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro Oncol. 2022 09 01; 24(9):1471-1481.  View on PubMed
  15. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 Oct; 144(4):747-765.  View on PubMed
  16. Calton B, Rabow M, Page M, Rossi R, Oberheim-Bush N, Chang S, Taylor JW. Embedding palliative care in a neuro-oncology clinic at an academic medical center: Our structure, experience, and lessons learned. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac114.  View on PubMed
  17. Bracci PM, Rice T, Hansen HM, Francis SS, Lee S, McCoy LS, Shrestha PP, Warrier G, Clarke JL, Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Pre-surgery immune profiles of adult glioma patients. J Neurooncol. 2022 Aug; 159(1):103-115.  View on PubMed
  18. Weyer-Jamora C, Brie MS, Luks TL, Smith EM, Hervey-Jumper SL, Taylor JW. In Reply: Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients. Neurosurgery. 2022 07 01; 91(1):e29.  View on PubMed
  19. Taylor JW. Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high-grade glioma? Neuro Oncol. 2022 03 12; 24(3):465-466.  View on PubMed
  20. Molinaro AM, Wiencke JK, Warrier G, Koestler DC, Chunduru P, Lee JY, Hansen HM, Lee S, Anguiano J, Rice T, Bracci PM, McCoy L, Salas LA, Christensen BC, Wrensch M, Kelsey KT, Taylor JW, Clarke JL. Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. J Natl Cancer Inst. 2022 03 08; 114(3):446-457.  View on PubMed

Go to UCSF Profiles, powered by CTSI